Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Vascular access–related complications remain a leading cause of hemodialysis-associated morbidity. However, limited evidence are available on vascular access outcomes in home hemodialysis (HHD) patients.
This cohort study, part of the Dutch nOcturnal and hoME dialysis Study To Improve Clinical Outcomes (DOMESTICO), included adult HHD patients (≥18 years) between April 1, 2018, and August 31, 2023, using either arteriovenous fistulas (AVFs) or central venous catheters (CVCs) as their primary hemodialysis access. The primary outcome was a composite event of vascular access–related complications requiring interventions, defined as the first occurrence of any of the following: percutaneous transluminal angioplasty, shunt surgery, catheter exchange, or infection-requiring treatment. Survival analysis followed the intention-to-treat approach. Kaplan–Meier curves and multivariable Cox regression was applied.
Among 54 HHD patients (63% AVFs and 37% CVCs), the incidence of composite complications requiring interventions was 18.3 events per 100 patient-year (95% confidence interval [CI]: 9.14-32.75) for AVFs and 12.2 events per 100 patient-years (95%CI: 3.31-31.11). The mean time to first intervention (primary patency) was 2.71 years (95%CI: 2.2-3.22) for AVFs and 3.59 years (95%CI: 2.93-4.25) for CVCs. The rate of infections requiring intervention was 0.07 per 1000 access days (95%CI 0.001-0.025) for AVFs and 0.23 per 1000 catheter days (95%CI: 0.005-0.068) for CVCs.
Among HHD patients, rates of vascular access–related complications requiring interventions, primary patency, and infection were not significantly different between AVF and CVC groups. These findings suggest that CVC maybe a suitable alternatives for patients opt for HHD without AVF.
